Epidemiology and genomic features of biliary tract cancer and its unique features in Korea
Biliary tract cancer (BTC) is a rare but highly aggressive malignancy that includes intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma, and gallbladder cancer (GBC). While BTC has a low global incidence, its regional variations are notable. Among nations, Korea has the second-hig...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Liver Cancer Association
2025-03-01
|
| Series: | Journal of Liver Cancer |
| Subjects: | |
| Online Access: | http://e-jlc.org/upload/pdf/jlc-2025-02-27.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850271364626251776 |
|---|---|
| author | Seonjeong Woo Youngun Kim Sohyun Hwang Hong Jae Chon |
| author_facet | Seonjeong Woo Youngun Kim Sohyun Hwang Hong Jae Chon |
| author_sort | Seonjeong Woo |
| collection | DOAJ |
| description | Biliary tract cancer (BTC) is a rare but highly aggressive malignancy that includes intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma, and gallbladder cancer (GBC). While BTC has a low global incidence, its regional variations are notable. Among nations, Korea has the second-highest incidence of BTC globally, with the highest mortality rate worldwide, underscoring the need for a deeper understanding of this cancer. Liver fluke infection and hepatitis B virus infection are key risk factors unique to Korea, contributing to regional differences in BTC incidence. Additionally, genomic alterations in Korean patients with BTC differ from those in other populations, including lower frequencies of IDH1 mutations and FGFR2 fusions in ICC and a higher prevalence of ERBB2 amplification in GBC. Recognizing the clinical significance of these alterations, ivosidenib and pemigatinib have been approved in Korea for BTC patients with IDH1 mutations and FGFR2 fusions, respectively. This review explores the epidemiology, risk factors, and molecular features of BTC, along with corresponding targeted therapies. Furthermore, we compare the unique characteristics of BTC in Korea with global data to inform future research and clinical practice. |
| format | Article |
| id | doaj-art-5149ec82068a4da4bd39bb44eb1012e7 |
| institution | OA Journals |
| issn | 2288-8128 2383-5001 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Korean Liver Cancer Association |
| record_format | Article |
| series | Journal of Liver Cancer |
| spelling | doaj-art-5149ec82068a4da4bd39bb44eb1012e72025-08-20T01:52:15ZengKorean Liver Cancer AssociationJournal of Liver Cancer2288-81282383-50012025-03-01251415110.17998/jlc.2025.02.27589Epidemiology and genomic features of biliary tract cancer and its unique features in KoreaSeonjeong Woo0Youngun Kim1Sohyun Hwang2Hong Jae Chon3 Department of Life Science, CHA University, Seongnam, Korea Department of Medical Oncology, CHA Bundang Medical Center, Seongnam, Korea Department of Pathology, CHA Bundang Medical Center, Seongnam, Korea Department of Medical Oncology, CHA Bundang Medical Center, Seongnam, KoreaBiliary tract cancer (BTC) is a rare but highly aggressive malignancy that includes intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma, and gallbladder cancer (GBC). While BTC has a low global incidence, its regional variations are notable. Among nations, Korea has the second-highest incidence of BTC globally, with the highest mortality rate worldwide, underscoring the need for a deeper understanding of this cancer. Liver fluke infection and hepatitis B virus infection are key risk factors unique to Korea, contributing to regional differences in BTC incidence. Additionally, genomic alterations in Korean patients with BTC differ from those in other populations, including lower frequencies of IDH1 mutations and FGFR2 fusions in ICC and a higher prevalence of ERBB2 amplification in GBC. Recognizing the clinical significance of these alterations, ivosidenib and pemigatinib have been approved in Korea for BTC patients with IDH1 mutations and FGFR2 fusions, respectively. This review explores the epidemiology, risk factors, and molecular features of BTC, along with corresponding targeted therapies. Furthermore, we compare the unique characteristics of BTC in Korea with global data to inform future research and clinical practice.http://e-jlc.org/upload/pdf/jlc-2025-02-27.pdfbiliary tract neoplasmsepidemiologygenomicsmolecular targeted therapykorea |
| spellingShingle | Seonjeong Woo Youngun Kim Sohyun Hwang Hong Jae Chon Epidemiology and genomic features of biliary tract cancer and its unique features in Korea Journal of Liver Cancer biliary tract neoplasms epidemiology genomics molecular targeted therapy korea |
| title | Epidemiology and genomic features of biliary tract cancer and its unique features in Korea |
| title_full | Epidemiology and genomic features of biliary tract cancer and its unique features in Korea |
| title_fullStr | Epidemiology and genomic features of biliary tract cancer and its unique features in Korea |
| title_full_unstemmed | Epidemiology and genomic features of biliary tract cancer and its unique features in Korea |
| title_short | Epidemiology and genomic features of biliary tract cancer and its unique features in Korea |
| title_sort | epidemiology and genomic features of biliary tract cancer and its unique features in korea |
| topic | biliary tract neoplasms epidemiology genomics molecular targeted therapy korea |
| url | http://e-jlc.org/upload/pdf/jlc-2025-02-27.pdf |
| work_keys_str_mv | AT seonjeongwoo epidemiologyandgenomicfeaturesofbiliarytractcanceranditsuniquefeaturesinkorea AT youngunkim epidemiologyandgenomicfeaturesofbiliarytractcanceranditsuniquefeaturesinkorea AT sohyunhwang epidemiologyandgenomicfeaturesofbiliarytractcanceranditsuniquefeaturesinkorea AT hongjaechon epidemiologyandgenomicfeaturesofbiliarytractcanceranditsuniquefeaturesinkorea |